Maraviroc

Generic Name
Maraviroc
Brand Names
Celsentri, Selzentry
Drug Type
Small Molecule
Chemical Formula
C29H41F2N5O
CAS Number
376348-65-1
Unique Ingredient Identifier
MD6P741W8A
Background

Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was ...

Indication

Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

Associated Conditions
CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

Maraviroc Efficacy for Hepatitis C

Phase 4
Completed
Conditions
Hepatitis C
Human Immunodeficiency Virus
Interventions
Drug: Maraviroc
First Posted Date
2016-08-29
Last Posted Date
2024-05-01
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
10
Registration Number
NCT02881762
Locations
🇺🇸

Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, Maryland, United States

Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation

First Posted Date
2016-06-15
Last Posted Date
2016-06-15
Lead Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Target Recruit Count
40
Registration Number
NCT02799888
Locations
🇨🇳

Department of Hematopoietic Stem Cell Transplantation, Beijing, Beijing, China

Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

Phase 1
Completed
Conditions
HIV Infections
Interventions
Drug: Maraviroc
First Posted Date
2016-05-19
Last Posted Date
2022-01-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
47
Registration Number
NCT02778204
Locations
🇺🇸

Usc La Nichd Crs, Los Angeles, California, United States

🇺🇸

St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States

🇰🇪

Kenya Medical Research Institute / Walter Reed Project Clinical Research Center, Kericho CRS, Kericho, Kenya

and more 6 locations

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

Phase 2
Completed
Conditions
HIV Infections
Kidney Diseases
Interventions
Drug: Placebo
Drug: Maraviroc
First Posted Date
2016-04-18
Last Posted Date
2023-08-21
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
97
Registration Number
NCT02741323
Locations
🇺🇸

UCLA HIVTR-CCR5 Non-Network CRS, Los Angeles, California, United States

🇺🇸

UAB HIVTR-CCR5 Non-Network CRS, Birmingham, Alabama, United States

🇺🇸

UCSF HIVTR-CCR5 Non-network CRS, San Francisco, California, United States

and more 7 locations

Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication

Early Phase 1
Terminated
Conditions
HIV-1 Infection
Interventions
Drug: Maraviroc
First Posted Date
2015-07-01
Last Posted Date
2015-12-18
Lead Sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Target Recruit Count
7
Registration Number
NCT02486510
Locations
🇪🇸

Hospital Universitario Ramon Y Cajal, Madrid, Spain

🇪🇸

Hospital Universitario La Paz, Madrid, Spain

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

First Posted Date
2015-06-25
Last Posted Date
2017-09-25
Lead Sponsor
ViiV Healthcare
Target Recruit Count
112
Registration Number
NCT02480894
Locations
🇺🇸

GSK Investigational Site, San Antonio, Texas, United States

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

First Posted Date
2015-06-19
Last Posted Date
2023-06-22
Lead Sponsor
SEARCH Research Foundation
Target Recruit Count
15
Registration Number
NCT02475915
Locations
🇹🇭

SEARCH, the Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

First Posted Date
2014-08-04
Last Posted Date
2019-01-23
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
279
Registration Number
NCT02208037
Locations
🇺🇸

University of Florida College of Medicine (Shands), Gainesville, Florida, United States

🇺🇸

Virginia Commonwealth University MCV Hospitals, Richmond, Virginia, United States

🇺🇸

University of North Carolina Hospital at Chapel Hill, Chapel Hill, North Carolina, United States

and more 27 locations

Maraviroc as GVHD Prophylaxis in Transplant Recipients

First Posted Date
2014-06-19
Last Posted Date
2020-03-10
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
31
Registration Number
NCT02167451
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Maraviroc and NeuroAIDS Pathogenesis

Phase 2
Completed
Conditions
AIDS Dementia Complex
Interventions
Drug: Placebo
Drug: Maraviroc
First Posted Date
2014-06-09
Last Posted Date
2021-08-30
Lead Sponsor
University of Hawaii
Target Recruit Count
48
Registration Number
NCT02159027
Locations
🇵🇷

Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico

🇺🇸

Clint Spencer Clinic, Hawaii Center for AIDS, University of Hawaii, Honolulu, Hawaii, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy